Why the study?
PAH rapidly deteriorates without treatment even in less advanced disease, motivating a review of evidence on the importance of early management in WHO functional class II patients.
Does early PAH-specific treatment improve outcomes in PAH patients with WHO FC II?
Does early PAH-specific treatment improve outcomes in PAH patients with WHO FC II?
This review highlights the critical importance of early initiation of PAH-specific therapy, particularly combination therapy, in patients with WHO FC II to improve long-term outcomes.
Answers are grounded in this paper and cite their sources.
Supports early PAH-specific therapy; extends evidence for prompt treatment to improve long-term survival.
Pulmonary arterial hypertension (PAH) is an incurable chronic and progressive debilitating disease associated with significant morbidity and mortality. The World Health Organization functional class (WHO FC) at diagnosis and at follow-up remains one of the strongest predictors of survival in PAH. Studies have shown improved long-term outcomes in PAH patients who received PAH-specific treatment, as monotherapy or as combination therapy, early in their disease course. Studies have also shown that without treatment, PAH rapidly deteriorates even in patients with less advanced (low risk) disease state. In this article, we review evidence from randomized controlled clinical trials to support our position on the importance of early PAH management in WHO FC II patients. The growing importance of combination therapy in the early treatment of PAH and recommendations by the most recent guidelines for the diagnosis and treatment of pulmonary hypertension are also discussed in this article.
No takes yet. Share an insight, caveat, or question.
Hung et al. (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: